Related Experiment Video
Updated: Jun 5, 2026

Detection of Neutralization-sensitive Epitopes in Antigens Displayed on Virus-Like Particle (VLP)-Based Vaccines Using a Capture Assay
Published on: February 10, 2022
Neutralizing antibodies elicited in nonhuman primates by an enterovirus D68 virus-like particle vaccine target
Daniel L Moss1, Jiaxuan Cheng1, Peter W Krug1
1Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, MD 20892, USA.
Abstract:
Enterovirus D68 (EV-D68) is a picornavirus that causes biennial outbreaks of respiratory disease in young children that can progress to rare but severe complications, including acute flaccid myelitis (AFM). EV-D68 virus-like particles (VLPs) elicit potent neutralizing antibodies that are protective in animal models. Here, we report the isolation and characterization of monoclonal antibodies elicited by EV-D68 VLPs in nonhuman primates (NHPs). We identified five potently neutralizing mAbs targeting overlapping epitopes near the capsid fivefold axis of symmetry formed by pentamers of viral protein 1. Cryo-electron microscopy structures of mAbs 1E11 and 5H03 in complex with VLP revealed epitopes on the capsid that bridge the sialic acid binding site and the proteinaceous entry receptor major facilitator superfamily domain-containing protein 6 binding site. We further characterized the mechanisms by which these mAbs neutralize EV-D68 and found that mAbs can disrupt multiple steps in the EV-D68 life cycle, including promoting premature uncoating. Antibodies elicited by VLP immunization of NHP protected as well as a best-in-class human mAb in a mouse challenge model, although single-amino acid mutations in the capsid enabled viral escape. Our results demonstrate that EV-D68 VLP-elicited mAbs target major viral sites of vulnerability, provide insight into their mechanisms of neutralization, and reinforce the potential for VLP-based vaccines as a countermeasure for EV-D68.
Insights
Monoclonal antibodies targeting Enterovirus D68 (EV-D68) virus-like particles (VLPs) show potent neutralization and protection in animal models. These antibodies disrupt viral entry and uncoating, highlighting VLP-based vaccines as a promising countermeasure for EV-D68.
Area of Science:
- Virology
- Immunology
- Vaccine Development
Background:
- Enterovirus D68 (EV-D68) causes respiratory illness in children, with potential for severe complications like acute flaccid myelitis (AFM).
- EV-D68 virus-like particles (VLPs) are known to induce protective neutralizing antibodies in preclinical models.
Purpose of the Study:
- To isolate and characterize monoclonal antibodies (mAbs) against EV-D68 elicited by VLP immunization in nonhuman primates (NHPs).
- To elucidate the neutralization mechanisms and epitope targets of these VLP-elicited mAbs.
Main Methods:
- Isolation and characterization of mAbs from immunized NHPs.
- Cryo-electron microscopy (cryo-EM) to determine mAb-VLP complex structures.
- In vivo challenge studies in a mouse model to assess protective efficacy.
Main Results:
- Five potent neutralizing mAbs were identified, targeting epitopes near the capsid's fivefold axis.
- Cryo-EM revealed mAb epitopes bridging sialic acid and receptor binding sites.
- mAbs demonstrated neutralization by disrupting multiple EV-D68 life cycle steps, including premature uncoating.
- VLP-elicited antibodies provided protection comparable to a human mAb in a mouse model, though viral escape was observed via single-amino acid mutations.
Conclusions:
- EV-D68 VLP-elicited mAbs target critical viral vulnerabilities and offer insights into neutralization mechanisms.
- These findings support the potential of VLP-based vaccines as effective countermeasures against EV-D68 infections.
Related Concept Videos
Cross-reactivity
Poliomyelitis
Respiratory Syncytial Virus Disease
